Patents by Inventor Charlie Buffie

Charlie Buffie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR REDUCING CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20230190825
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Application
    Filed: October 17, 2022
    Publication date: June 22, 2023
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • Methods and compositions for reducing infection
    Patent number: 11471495
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 18, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • METHODS AND COMPOSITIONS FOR REDUCING CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20190381113
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Application
    Filed: July 26, 2019
    Publication date: December 19, 2019
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • METHODS AND COMPOSITIONS FOR REDUCING CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20170087196
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 30, 2017
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney